Sweden · Delayed Price · Currency is SEK Elicera Therapeutics AB Company Description
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden.
The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer.
It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors.
Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials.
The company was incorporated in 2014 and is based in Gothenburg, Sweden.
| Country | Sweden |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Jamal El-Mosleh |
Contact Details
Address: World Trade Center Göteborg Gothenburg, 412 51 Sweden | |
| Phone | 46 7 03 31 90 51 |
| Website | elicera.com |
Stock Details
| Ticker Symbol | ELIC |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0015382080 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jamal El-Mosleh M.Sc. | Chief Executive Officer and Co-Founder |
| Prof. Magnus Essand | Chief Science Officer, Co-Founder and Director |
| Di Yu | Co-Founder and Head of Transitional Research |
| Ingvar Karlsson | Chief Financial Officer |
| Anna Koptina Gultekin | Head of Regulatory Affairs |